Skip to Content
  • Article
  • Open Access

18 October 2021

12 Pages

Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies

,
,
,
,
,
,
,
,
and
1
Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3084, Australia
2
La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia
3
School of Medicine, Tokai University, Isehara-City 259-1193, Japan
4
CancerProbe Pty Ltd., Prahran, VIC 3181, Australia

Abstract

Ovarian cancers include several disease subtypes and patients often present with advanced metastatic disease and a poor prognosis. New biomarkers for early diagnosis and targeted therapy are, therefore, urgently required. This study uses antibodies produced locally in tumor-draining lymph nodes (ASC probes) of individual ovarian cancer patients to screen two separate protein microarray platforms and identify cognate tumor antigens. The resulting antigen profiles were unique for each individual cancer patient and were used to generate a 50-antigen custom microarray. Serum from a separate cohort of ovarian cancer patients encompassing four disease subtypes was screened on the custom array and we identified 28.8% of all ovarian cancers, with a higher sensitivity for mucinous (50.0%) and serous (40.0%) subtypes. Combining local and circulating antibodies with high-density protein microarrays can identify novel, patient-specific tumor-associated antigens that may have diagnostic, prognostic or therapeutic uses in ovarian cancer.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.